A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture by Wagner, Ilka et al.
ISSN 1473-0197
Lab on a Chip
Miniaturisation for chemistry, physics, biology, materials science and bioengineering
www.rsc.org/loc Volume 13 | Number 18 | 21 September  2013 | Pages 3435–3766
PAPER
Ilka Wagner et al.
A dynamic multi-organ-chip for long-term cultivation and substance testing 
proven by 3D human liver and skin tissue co-culture 
LC013018_cover_PRINT.indd   2 8/8/2013   1:30:09 PM
Cite this: Lab Chip, 2013, 13, 3538
A dynamic multi-organ-chip for long-term cultivation
and substance testing proven by 3D human liver and
skin tissue co-culture
Received 20th February 2013,
Accepted 28th March 2013
DOI: 10.1039/c3lc50234a
www.rsc.org/loc
Ilka Wagner,3*a Eva-Maria Materne,3a Sven Brincker,a Ute Su¨ßbier,a
Caroline Fra¨drich,a Mathias Busek,ab Frank Sonntag,b Dmitry A. Sakharov,c Evgeny
V. Trushkin,c Alexander G. Tonevitsky,d Roland Laustera and Uwe Marxa
Current in vitro and animal tests for drug development are failing to emulate the systemic organ
complexity of the human body and, therefore, to accurately predict drug toxicity. In this study, we present
a multi-organ-chip capable of maintaining 3D tissues derived from cell lines, primary cells and biopsies of
various human organs. We designed a multi-organ-chip with co-cultures of human artificial liver
microtissues and skin biopsies, each a 1/100 000 of the biomass of their original human organ counterparts,
and have successfully proven its long-term performance. The system supports two different culture modes:
i) tissue exposed to the fluid flow, or ii) tissue shielded from the underlying fluid flow by standard
Transwell1 cultures. Crosstalk between the two tissues was observed in 14-day co-cultures exposed to
fluid flow. Applying the same culture mode, liver microtissues showed sensitivity at different molecular
levels to the toxic substance troglitazone during a 6-day exposure. Finally, an astonishingly stable long-
term performance of the Transwell1-based co-cultures could be observed over a 28-day period. This mode
facilitates exposure of skin at the air–liquid interface. Thus, we provide here a potential new tool for
systemic substance testing.
Introduction
New solutions are needed to ban the ever increasing dilemma
of poorly predictive preclinical substance evaluation generated
by the phylogenetic distance between laboratory animals and
humans, the discrepancy between current in vitro systems and
the human body, and the restrictions of in silico modelling.
Although it is an ambitious project, the development of
‘‘human-on-a-chip’’ systems has been recognised as an ideal
path to escape from this dilemma.1–3 These ‘‘human-on-a-
chip’’ systems combine two essential requirements: i) the
improvement of the organotypical nature of single organ
equivalents, and ii) the linking of different organs into a
systemic arrangement reflecting that of the human organism
at a miniaturised scale. Only a few multi-compartment cell
culture flow systems for the simultaneous co-culture of
different tissues have been described on a miniaturised scale
so far.4–7 The majority expose tissues to laminar flow within
microchannels.3,5,8 The advantage of these multi-organ sys-
tems is an explicit adjustable fluid flow and a controllable
local tissue-to-fluid ratio in the channels. However, these
systems suffer from reduced cross-conditioning and molecular
crosstalk among tissues, due to a small cell count (mostly
below ten thousand) and a significant dilution. Tissue cross-
talk has been reported by Guzzardi et al.11 in a system hosting
2.4 6 105 liver cells and 8 6 104 endothelial cells in separate
compartments with a total circulating volume of 30 ml
medium. Tissue volumes in those systems represent only a
very tiny fraction of the overall circulating media volume due
to the use of external pumps and external media reservoirs.
To solve this problem, we integrated a peristaltic micro-
pump and media reservoirs into a chip the area of a standard
microscope slide, in order to minimise the fluid-to-tissue ratio
within the whole system and to ensure a selectable number of
media flow velocities. This multi-organ-chip (MOC) combines
the on-chip micropump with various arrangements of separate
standardised tissue culture spaces connected by microfluidic
channels. Of several designs produced, the two-tissue MOC
design was chosen to prove the capability of the MOC platform
to simultaneously maintain a human liver equivalent and a
human skin biopsy. The liver is the prime target for toxicity
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evaluation of pharmaceutical drug candidates and human skin
is the target tissue for cosmetics. The human hepatocyte cell
line, HepaRG, primary human hepatic stellate cells (HHSteC)
and freshly generated skin biopsies were cultured simulta-
neously to demonstrate the comprehensiveness of the MOC
system with regard to tissue sources. Each of the perfused
MOC tissue culture compartments was designed the scale of a
single well of a standard 96-well plate to fit industrially applied
standard formats of in vitro culture. This allowed the direct
exposure of co-cultures to fluid flow at the bottom of the
compartments and the co-culture to be shielded from the
underlying fluid flow by standard Transwell1 inserts. The
latter mode, in addition, facilitates the culture of skin at the
air–liquid interface. Furthermore, the MOC device’s stable
long-term performance enables repeated dose exposure of
tissues to troglitazone, a diabetic drug with well-known dose-
dependent liver toxicity.
Materials and methods
Device design and fabrication
We established a rapid prototyping procedure for the flexible
fabrication of various designs of MOCs. A single 2 mm high
polydimethylsiloxane (PDMS) layer containing the respective
arrangement of channels, micropumps and openings for
culture compartments (Fig. 1a) was permanently bonded by
low pressure plasma oxidation (Femto; Diener, Ebhausen,
Germany) to a glass microscope slide with a footprint of 756
25 mm (Menzel, Braunschweig, Germany), thus forming the
respective fluid-tight microfluidic MOC device with standard
channel heights of 100 mm. The peristaltic on-chip micropump
was modified from Wu and co-workers9 and represents three
500 mm thick PDMS membranes in a row. They are
consecutively actuated by applying pressure. Up to seven
tissue culture compartments have been designed into MOC
devices for different applications (larger black areas of each
design in Fig. 1a). The design consisting of two culture
compartments per co-culture circuit (Fig. 1a, top image) was
used in the experiments reported here. The MOCs were
fabricated applying standard soft lithography and replica
moulding of PDMS (Sylgard 184, Dow Corning, Midland, MI,
USA). In brief, a master mould was fabricated by bonding a
silicon wafer to a glass wafer. Photoresist was applied to the
silicon wafer and patterned by using a photomask and UV
light. Subsequently, unprotected silicon regions were etched
and the photoresist was stripped. The fabrication of the
microsystem was as follows: A polycarbonate cover-plate was
treated with a silicon rubber additive (WACKER1 PRIMER G
790; Wacker Chemie, Munich, Germany) at 80 uC for 20 min.
Teflon screws were inserted to create four PDSM-free
compartments for culture and six 500-mm thick PDMS
membranes to connect the micropumps. The prepared cover-
plate was plugged to the master mould (channel height 100
mm, width 500 mm) and PDMS (10 : 1 v/v ratio of PDMS to
curing agent) was injected into this casting station. The set-up
was incubated at 80 uC for 60 min and, subsequently, bonded
to the glass slide. A schematic drawing of the final MOC device
is illustrated in Fig. 1b and highlights the fluid flow directions.
Fig. 1c illustrates the culture compartments, each designed to
hold a maximum of 300 ml medium. The direct exposure of
Fig. 1 The microfluidic MOC device at a glance. a) Bird’s-eye view of three different MOC designs. b) 3D drawing of an assembled MOC with two microfluidic circuits
in a PDMS-glass chip attached to a cover-plate and placed into a MOC holder (blue). Arrows indicate fluid flow direction of each circuit. S-skin culture compartments,
L-liver culture compartments c) Schematic sections through the tissue culture compartments supporting both submersed tissue cultures in the fluid flow (left image)
or cultures in Transwell1 (right image).
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tissue to fluid flow (left side) and the alternative co-culture
setting in Transwell1 separating tissues from the fluid flow by
a 10 mm porous membrane (right side) are highlighted.
Cell sources and maintenance
Cell culture components were purchased from PAA
Laboratories (GE Healthcare Europe GmbH, Vienna, Austria)
and cultures were incubated in HepaRG medium at 37 uC and
5% CO2, unless otherwise stated. HepaRG cells were obtained
from Biopredic International (Rennes, France) and maintained
as described by Gripon et al.10 Briefly, cells were cultured in
HepaRG medium, consisting of William’s Medium E supple-
mented with 10% foetal calf serum, 100 units per ml
penicillin, 100 mg ml21 streptomycin, 5 mg ml21 human
insulin, 2 mM L-glutamine, and 5 6 1025 M hydrocortisone
hemisuccinate (Sigma-Aldrich, St. Louis, MO, USA).
Undifferentiated cells were maintained in 75 cm2 tissue
culture flasks (Greiner Bio One, Germany) at a seeding density
of 2 6 104 cells cm22 for two weeks, according to the
manufacturer’s instructions. Medium was renewed every 2 or 3
days. Induction of differentiation was initiated by maintaining
the cells in growth medium for 2 weeks with a regular media
exchange every 2 or 3 days in order to reach cellular
confluence. Differentiation medium containing 2% dimethyl
sulfoxide (DMSO; Carl Roth GmbH, Karlsruhe, Germany) was
then added for a cultivation period of 2 weeks. When
differentiation was completed, the cells were used for further
experiments. Human hepatic stellate cells (HHSteC) and their
culture supplements were purchased from ScienCell Research
Laboratories (Carlsbad, CA, USA). The cells were seeded at 56
103 cells cm22 in poly-L-lysine-coated 75 cm2 tissue culture
flasks in stellate cell medium for maintenance, according to
the manufacturer’s instructions. Medium was exchanged every
2 or 3 days. Cells were harvested for further use at 90%
confluence. Human juvenile prepuce was obtained in com-
pliance with the relevant laws, with informed consent and
ethics approval (Ethic Committee Charite´ University Medicine,
Berlin, Germany), from a paediatric surgery after routine
circumcisions. Prepuce samples with an average size of 2.5
cm2 were stored and transported in 10 ml phosphate-buffered
saline (PBS) at 4 uC and prepared for further culture within 4 h
following surgery.
Preparation of skin biopsies
Prepuce samples were sterilised in 80% ethanol for 30 s.
Samples with an average height of 2 mm were punched to
biopsies with 4 or 5 mm diameter, depending on the culture
set-up chosen. One biopsy was loaded into a single MOC
culture compartment for cultivation. Samples from one donor
were used for each MOC-based test series and the respective
control in static culture (punches from Stusche, Teltow,
Germany).
Formation of human artificial liver microtissues
Liver microtissue aggregates were formed in Perfecta3D1 384-
Well Hanging Drop Plates (3D Biomatrix, Ann Arbor, MI, USA),
according to the manufacturer’s instructions. Briefly, 20 ml cell
suspension containing 4.8 6 104 hepatocytes and 0.2 6 104
HHSteC were pipetted to each access hole. After two days of
hanging drop culture, aggregates were transferred to ultra-low
attachment 24-well plates (Corning, Lowell, MA, USA) with a
maximum of 20 aggregates per well. Following culture in ultra-
low attachment wells for 3 days, 20 aggregates were loaded
into a single tissue culture compartment of the MOC.
Multi-tissue culture directly exposed to fluid flow in the MOC
device
Liver microtissues (20 aggregates per compartment) and a 4
mm skin biopsy (one biopsy per compartment) were loaded
into the respective culture compartment of the two circuits of
each MOC device (Fig. 1b) for co-culture. Additional MOCs
were loaded solely with liver microtissue and solely with skin
biopsies for comparison. Subsequently, 300 ml of medium was
added to each culture compartment, which was then herme-
tically sealed by a lid. During the first 7 days, a 40% media
exchange rate was applied at 12 h intervals. From day 7
onwards, a 40% exchange rate was applied at 24 h intervals.
Daily samples were collected for respective analyses.
Experiments were stopped at day 14 of co-culture and tissues
of the MOCs were subjected to immunohistochemical stain-
ings. Experiments were conducted with six replicates.
Multi-tissue exposure to troglitazone
Troglitazone was dissolved in DMSO, stored frozen at a
concentration of 20 mM until use, and then diluted in culture
medium to a level of 0.05% DMSO. Medium containing 0.05%
DMSO was used for control cultures. Liver microtissue and
skin biopsy co-cultures in MOCs were prepared, cultured and
analysed as described above. The contents in the MOCs were
cultured for one day prior to exposure and were, subsequently,
exposed to 0 mM, 5 mM and 50 mM troglitazone, respectively.
Application of troglitazone was repeated at 12 h intervals
simultaneously with the medium change. The experiments
were stopped at day 7. Cell viability and protein expression
were assessed by immunohistochemistry and quantitative PCR
(qPCR). Experiments were performed in quadruplicate.
Transwell1 multi-tissue culture in the MOC device
Liver microtissues and skin biopsies were cultured for
cosmetic compliance each in a separated single insert of a
96-well Transwell1 unit (Corning), which was hung inside the
chip with the membrane fitting directly over the circuit. The
height of the tissue and the amount of medium added to the
Transwell1 enabled the tissue to be either air–liquid inter-
faced (skin) or submerged in media (liver equivalent).
Compartments for tissue culture were filled with 200 ml
medium each to inoculate the MOC. Two wells per circuit from
a 96-well Transwell1 plate (0.4 mm pore size) were cut below
the bracket with an incandescent knife and removed. Prepared
liver spheroids and epidermal-side up skin tissues with a
diameter of 5 mm were transferred into the excised
Transwell1 which were positioned into the transwell-holders
and screwed into the MOC. The medium was exchanged every
12 h within the first 7 days and every 24 h afterwards, as
described above. Supernatants were collected every day for
lactate and glucose measurements. At the end of the 28-day
culture, cell viability and protein expression were assessed via
3540 | Lab Chip, 2013, 13, 3538–3547 This journal is  The Royal Society of Chemistry 2013
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immunohistochemistry. The experiments were conducted in
quadruplicate.
Tissue culture analyses
Tissue viability was monitored daily by the measurement of
lactate dehydrogenase (LDH) released in the supernatant. In
brief, samples were immediately measured for LDH concen-
tration and then stored at 280 uC for further analysis of
glucose, lactate and albumin. All absorbance-related measure-
ments were performed in 96-well microtitre-plates (Greiner
Bio-One, Frickenhausen, Germany) in a microplate-reader
(FLUOstar Omega, BMG Labtech, Ortenberg, Germany), if
not stated otherwise. The LDH concentration of the medium
was measured using the LDH Liqui-UV kit (Stanbio Laboratory,
Boerne, USA), according to the manufacturer’s instructions
with minor modifications based on our own standard curves:
An amount of 100 ml of reagent was used and 1 ml of the
sample was added for each measurement.
Furthermore, tissue behaviour, apoptosis and proliferation
were analysed by immunohistological end-point stainings at
the end of each MOC experiment using TUNEL (TdT-mediated
dUTP-digoxigenin nick end labelling)/Ki67 markers. Briefly,
representative central sections of the tissue of each sample
were selected for staining. Eight-micron cryostat sections per
sample of skin and liver were stained for apoptosis using the
TUNEL technique (ApopTag1 Peroxidase In Situ Apoptosis
Detection Kit, Merck Millipore, Darmstadt, Germany) accord-
ing to the manufacturer’s instructions. The apoptosis staining
was combined with a nuclear stain, Hoechst 33342 (Life
Technologies, Darmstadt, Germany), and, where sections were
also stained for proliferation, an antibody Ki67 (Abcam,
Cambridge, UK). The sections were fixed in acetone at 220
uC for 10 min, washed with PBS and blocked with 10% goat
serum in PBS for 20 min, then incubated with rabbit anti-
human Ki67 antibody at 4 uC overnight. The sections were
washed and incubated with secondary antibody goat anti-
rabbit IgG Alexa Fluor1 594 (Life Technologies) for 45 min,
washed, incubated with Hoechst 33342 dye (10 mg ml21 in PBS)
for 10 min and washed again before fluorescence imaging.
Glucose consumption, lactate production and albumin
synthesis was monitored daily to assess the metabolic activity
of the tissues in the MOC. The Glucose LiquiColor1 Oxidase
kit (Stanbio Laboratory, Boerne, USA) was used with minor
modifications: An amount of 100 ml of reagent was used and 1
ml of sample was added. Lactate concentration of the medium
was measured using the LAC 142 kit (Diaglobal, Berlin,
Germany), according to the manufacturer’s instructions with
minor modifications based on our own standard curves: An
amount of 99 ml of the reagent was mixed with 1 ml of sample
and absorbance was measured at 520 nm, using medium as a
reference. The Human Albumin ELISA Quantitation Set (Bethyl
Laboratories, Montgomery, USA) was used to measure the
albumin concentration, according to the manufacturer’s
instructions.
Real-time qPCR endpoint analyses were performed to
evaluate liver gene transcription at mRNA level after the MOC
cultures were stopped as follows: Liver equivalents were collected
for RNA isolation using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). cDNA was synthesised by reverse transcription of 400
ng total RNA (TaqMan1, Roche Diagnostics, Mannheim,
Germany). Real-time qPCR experiments were conducted by using
the Stratagene system (Agilent Technologies, Bo¨blingen,
Germany) and the SensiFast SYBR No-ROX One-Step Kit
(Bioline, Luckenwalde, Germany) according to the manufac-
turer’s instructions. The real-time qPCR primers were as follows:
cytochrome P450 3A4 forward; 59-GGAAGTGGACCCAGAAACTGC
and reverse 59-TTACGGTGCCATCCCTTGAC, Housekeeping
gene: TBP (TATA box binding protein) forward 59 CCTTG-
TGCTCACCCACCAAC 39 and reverse 59TCGTCTTCCTGAAT-
CCCTTTAGAATAG 39.
Finally, in-depth immunohistochemical end-point analyses
were performed by staining the liver tissue sections for the
functional markers cytochrome P450 3A4 and 7A1, the tight
junction associated protein ZO-1 and the transporter MRP2,
and for the structural proteins cytokeratin 8/18 and vimentin.
Skin tissue sections were stained for the epidermal structural
proteins cytokeratin 10 and 15. Briefly, representative central
cryosections of the tissues were fixed and blocked following
the same methods as described for the Ki67 staining. Skin
sections were then incubated with mouse anti-human
Cytokeratin 10 (Millipore, Billerica, USA) and rabbit anti-
human Cytokeratin 15 (Abcam, Cambridge, UK) antibody for 2
h and washed with PBS. Subsequently, goat anti-rabbit IgG
Alexa Fluor1 594 (Life Technologies) and goat anti-mouse IgG
fluorescein isothiocyanate (FITC) (BD Biosciences, Heidelberg,
Germany) conjugated secondary antibodies and Hoechst
33342 were added, and the sections were incubated for 45
min before fluorescence imaging. The same procedure was
carried out for liver equivalents using mouse anti-human
cytochrome P450 3A4, rabbit anti-human cytochrome P450
7A1, rabbit anti-human ZO-1, rabbit anti-human MRP2, mouse
anti-human cytokeratin 8/18, and rabbit anti-human vimentin
(all antibodies purchased from Santa Cruz Biotechnology,
Heidelberg, Germany). Conjugated secondary antibodies goat
anti-mouse IgG Alexa Fluor1 594, goat anti-rabbit IgG Alexa
Fluor1 594 and goat anti-rabbit IgG Alexa Fluor1 488 (all
purchased from Life Technologies) were used for visualisation.
Results and discussion
Features of the MOC design
The newly designed MOC platform presented here combines a
flexible microfluidic channel system (100 mm high) operated
by an on-chip micropump with multiple separate tissue
culture compartments, each the size of one cavity of a
standard 96-well microplate. The design aims to provide two
important physiological features: mechanical coupling of
tissues and their molecular crosstalk with each other. The
standard tissue culture format easily enables researchers to
combine validated static tissue cultures of different origin
within a common fluid flow (e.g. human 3D liver spheroids,
Transwell1-based human epidermis and CaCo2-cell barrier
models). We have prototyped different MOC designs with up
to seven separate tissue culture compartments (Fig. 1a) for
various applications so far. Data in this paper are acquired
with the microfluidic MOC device (Fig. 1b) consisting of two
This journal is  The Royal Society of Chemistry 2013 Lab Chip, 2013, 13, 3538–3547 | 3541
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separate circuits each containing two tissue culture compart-
ments. Two alternative culture modes with and without use of
a Transwell1 insert are applicable in each culture compart-
ment (Fig. 1c). The tissue volume cultivated in the system is 26
ml per circuit for the liver and skin tissue co-cultures. The total
extra-cellular fluid volume is 600 ml per circuit without the
Transwell1 and 400 ml per circuit using the Transwell1 insert
in each compartment, whereof the channel connecting the two
tissues (equivalent to intra-capillary fluid volume) has a
volume of 10 ml. This corresponds to a total systemic media-
to-tissue ratio of 23 : 1 or 15 : 1, respectively, for the liver and
skin tissue co-cultures. In humans, regarding a 73 kg man, the
total extra-cellular fluid volume is 14.6 l, whereof the inter-
capillary fluid volume is 5.1 l. Therefore, the physiological
extracellular fluid to tissue ratio would be 1 : 4. In the MOC,
the excess amount of media is due to the media demand of the
tissue. The micropump provides a stable pulsatile fluid flow at
a circulation rate of 40 ml min21 through the microchannel
system supporting a total volume perfusion in 10 min (with
Transwell1 inserts) or 15 min (without Transwell1 inserts).
The mechanical coupling of tissues has been shown to be an
important physiological factor for functional tissue behaviour
in almost all organs at various degrees.7 Domansky and
colleagues adopted mechanical coupling to a multiwell plate
for 3D liver tissue engineering. Inside the bioreactors, a
scaffold made of an ECM-coated polymer with an array of 769
microchannels (0.24 mm depth, 0.34 mm diameter) was
supported below by a filter with 5 mm pore size.
Approximately 106 cells of a hepatocyte–sinusoidal endothelial
cell co-culture were perfused with a total volume of 3 ml media
per bioreactor.12 Unfortunately, this system does not provide
the option to combine two or more separate tissue culture
compartments. In contrast to the devices described above, our
MOC system provides a low systemic media-to-tissue ratio with
the flexibility to combine different standard tissue cultures. In
addition to the liver and skin tissue co-culture reported here,
the combination of, for example, commercial Transwell1
barrier models of intestine with submersed liver microtissue
cultures is envisaged. This might support further investiga-
tions into systemic organ interactions for substance exposure.
Furthermore, it might be of interest to study skin permeability
of cosmetics with a representative number of perfused human
epidermal skin equivalents in respective arrangements.
Robustness of tissue preparation
Skin biopsy preparation was established for more than 30
biopsies with 100% nondissipative and contamination-free
preparations and applications within one year. Biopsies of 4
and 5 mm diameter – different sizes for technical use – were
prepared, representing 1/100 000 of the human skin area. A 5
mm diameter biopsy has a tissue volume of 24 ml and consists
of approximately five million cells. Unlike commercially
available skin models, the prepuce contains apocrine glands,
which produce lysozymes, neutrophil elastases, and cyto-
kines.13 In addition, it has numerous specialised nerve
endings in vivo. Furthermore, adult stem cells, which are
capable of regenerating the epidermis, are present in their
specific quiescent-promoting niches in the prepuces. This
heterogeneity of the original tissue supports different cellular
and molecular events in the respective biopsies. Donor-specific
variations may explain the high variances for certain data
points.
Consistent disk-shaped liver cell aggregates with a medium
diameter of 300–400 mm and a height of 200–300 mm were
formed during 2 days of hanging drop culture (Fig. 2a). A
reliable production of 300 spheres per plate was achieved. One
tissue culture compartment of each MOC circuit was seeded
with 106 cells corresponding to 20 aggregates, which matches
an equal miniaturisation ratio for both skin and liver.
Immunohistochemical stainings of vimentin and cytokeratin
8/18 revealed that the HHSteCs were distributed equally
throughout the whole aggregate (Fig. 2b). ZO-1 staining
showed that cell–cell contact supports tight junctions devel-
oped during culture (Fig. 2c). Positive staining for MRP-2
demonstrates the polarisation of cells and the existence of
rudimentary bile canaliculi-like networks in the generated liver
microtissues (Fig. 2d).
Performance of fluid flow exposed multi-tissue cultures over
14 days
The human liver and skin tissue co-cultures were maintained
in all MOCs during the experimental period of 14 days (Fig. 3).
A constant LDH level of about 20 U L21 from cultivation day 6
onwards indicates an artificial but stable tissue turnover in the
system. Cell death within this steady state happened primarily
in the skin culture compartment, as data from MOC single-
tissue cultures of skin suggest (data not shown). A possible
explanation might be an increased epidermis turnover
induced by the artificial culture conditions, such as artificial
shear stress and lack of air exposure to the epidermal surface
of skin biopsies. It is interesting that this steady tissue
Fig. 2 Formation of human artificial liver microtissues over 2 days. a) Light
microscopy of a human liver spheroid generated by a standardised hanging
drop culture. Scale bar: 100 mm. b) Equal distribution of HHSteCs throughout
the HepaRG cell aggregate at a 1 : 24 ratio demonstrated by immunostaining
of vimentin (red) and cytokeratin 8/18 (green), blue nuclear staining. Scale bar
100 mm. c) Characteristic formation of tight junctions (protein ZO-1, red), blue
nuclear staining. Scale bar 50 mm. d) Expression of canalicular transporter MRP2
(green), blue nuclear staining. Scale bar 50 mm.
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turnover was not affected when the daily MOC feeding rate was
reduced by half starting on day 7 of culture. Metabolic activity
of the MOC co-cultures also showed a biphasic profile with a
period of higher but constantly decreasing activity until day 7
and a steady state with low fluctuations both for lactate
production and glucose consumption (Fig. 3a). Notably, the
steady state phase here coincides with the change of the
feeding regimen at the same day.
The glucose metabolism in human hepatocytes in vivo is a
complex and strictly regulated process. Hepatocyte sources,
culture microenvironment and media composition severely
alter the glucose metabolism of hepatocytes in vitro. Both
consumption and release are described for in vitro hepatocyte
cultures.14 The liver microtissues used in this study did not
show measurable signs of glucose release in any of the
experimental settings reported here. We cannot exclude
ongoing active glucose release processes in the culture, as
they might be hidden due to the immediate consumption by
neighbouring HHSteCs. Analyses of the lactate production rate
in separate single-tissue MOC-based cultures revealed an
average of ca. 210 mg per day per circuit for the liver
microtissues and 240 mg per day per circuit for skin biopsy
cultures at steady state (data not shown). The lactate
production profile in co-culture (Fig. 3a) at a steady state
(day 8 onwards) had an average value of 350 mg per day per
circuit. This slight decrease in lactate production in the co-
culture might point to conditional effects between the skin
and the liver tissue. The near to steady state consumption of
glucose and production of lactate by the co-cultures from day 8
onwards indicates the establishment of a stable artificial
coexistence between the two tissues. Preliminary experiments
using fluorescence quenching (Presens GmbH, Regensburg,
Germany) revealed no oxygen limitation in the circulating
media (data not shown). However, inner cells of skin biopsies
and liver spheroids might experience reduced oxygen concen-
trations and might contribute to glycolytic transformation
from glucose to lactate.
Albumin synthesis has been selected out of a wide range of
functional liver cell activity markers to monitor liver-like
activity in the MOC co-cultures (Fig. 3b). The unexpected high
amount of albumin in the first 2–3 days of co-culture can be
clearly explained by albumin released from the skin biopsies,
because the single skin cultures exhibit exactly the same
profile. These amounts of albumin are eventually released
from the inner lumen of the damaged microvessels of the skin
and the extra capillary depots. Strikingly, the albumin profile
of the single skin cultures at days 4, 5 and 6 substantiate a
pronounced consumption of albumin by the skin. This
observation was perfectly matched by the parallel albumin
profile of the co-culture at slightly higher absolute amounts.
This suggests that the albumin consumed by skin in the co-
cultures is provided by the active production of the respective
liver compartment. The constant albumin production in single
liver tissue culture further backs up this hypothesis. Finally,
the crosstalk between liver and skin within the co-culture
steadies, and albumin concentration stays close to zero (0.15
mg per day per circuit at day 7 and 0.13 mg per day per circuit at
day 14), which we interpret as equilibrium between albumin
production by liver and immediate consumption of the same
amount of albumin by skin. This matches the well-known facts
that albumin is degraded by skin fibroblasts and, furthermore,
that nearly 50% of the extravascular albumin in humans is
stored in the skin.15 Albumin is absorbed by the network of
collagen, proteoglycans and hyalurons in vivo, and its content
increases with overhydration in human skin by 20–30%.15
Therefore, skin biopsies in submerged culture can act as an
albumin depot. It remains unclear if skin would be able to
absorb even larger amounts of albumin, but this finding again
underscores the stable coexistence between the two tissues. It
is interesting that albumin synthesis in liver single-organ MOC
cultures exhibits values (3.5 mg per day per circuit at day 7 and
6.8 mg per day per circuit at day 14) consistent with those
shown in the literature.14
Fig. 3 14-day tissue performance at direct exposure to fluid flow. a) Glucose, lactate and LDH metabolic activity of MOC co-cultures. b) Albumin profiles of liver and
skin single-cultures and liver and skin co-cultures in MOC. Data are means ¡ SEM (n = 6).
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Multi-tissue sensitivity to troglitazone at fluid flow
Troglitazone was chosen to explore whether the MOC system is
suitable for repeated dose substance testing. Its dose-
dependent toxicity on HepaRG cells in vitro has been described
elsewhere.16 We decided to expose the MOC co-cultures to
troglitazone during the first 7 unsettled days of co-culture,
because we hypothesised a higher sensitivity to a toxic agent at
this stage. Nevertheless, troglitazone had no significant effect
on the metabolic activity of liver and skin co-cultures. After 4
days of culture, we observed an increase of LDH activity and
after 7 days a significant 60% increase when compared to
DMSO-treated controls.
The most sensitive indicator for dose-dependent sensitivity
of the MOC co-cultures could be identified on mRNA levels in
the respective liver microtissues after cultivation at day 7.
qPCR analysis of cytochrome P450 3A4 and immunohisto-
chemistry showed increased expression of this enzyme on
mRNA and protein levels in cultures exposed to 50 mM
troglitazone (Fig. 4e). This upregulation of biotransformation
activity following troglitazone treatment has been shown
before16,17 and indicates a typical reproduction of the toxic
mechanism in vivo. In contrast to Hewitt et al.,18 we could not
detect a pronounced increase of glucose consumption induced
by 50 mM troglitazone. The fact that this gene upregulation was
not evident on the global metabolic level (in terms of glucose
and lactate) might point to a labour division among the
HepaRG cells within the microtissues. This hypothesis was
disproven by immunohistochemical staining of representative
liver microtissue sections after completion of the culture. An
evenly distributed overexpression of cytochrome P450 3A4
activity could be detected in all the MOCs exposed to 50 mM
troglitazone, whilst only minute expression was detectable in
the control group. The experiments revealed a sensitivity of the
MOC co-cultures of liver and skin equivalents to a liver toxic
substance at different levels of analyses. Long-term analyses
extended toward the steady state phase and use of higher
doses might give additional insights into the artificial multi-
tissue homeostasis in MOCs in further studies.
Performance of Transwell1 multi-tissue cultures over 28 days
OECD guidelines for dermal subsystemic repeated dose
toxicity testing of chemicals and cosmetics in animals require
21–28 days of exposure (OECD guideline no. 410, ‘‘Repeated
Fig. 4 Sensitivity to troglitazone after 6 days of repeated dose exposure. a) Glucose consumption and b) Lactate production profiles c) LDH values d) Real-time qPCR
of the cytochrome P450 3A4 e) Immunostaining of cytochrome P 450 3A4 in control (left) compared to the 50 mM troglitazone exposed group (right), nuclear stain
blue. Scale bar 100 mm. c) Statistical analysis was performed by one-way analysis of variance (ANOVA), followed by post-hoc Dunnett’s pairwise multiple comparison
test. *P , 0.05 versus control. (a, b and c) Data are means ¡ SEM (n = 4).
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Dose Dermal Toxicity: 21/28-day Study’’). We decided to focus
on two pivotal aspects to converge our culture system to the
current standard animal tests to analyse the long-term
performance of MOC-based human liver and skin co-cultures:
i) to provide an air–liquid interface for the skin culture for
later dermal substance exposure, and ii) to strictly adhere to
the required timeline of 28 days of substance exposure. To do
so, we decided to use Transwell1 inserts to culture liver and
skin over this extended period. This would ultimately lead to
reduced shear stress and different nutrient supply character-
istics in the MOCs. A robust steady state metabolic activity
from day 8 onwards throughout the entire culture process
could be observed, with the glucose consumption averaging at
approximately 400 mg per day per MOC circuit and lactate
production averaging at 200 mg per day per MOC circuit. This
is about 40% lower than the corresponding values of the 14
day studies and 50% lower than those of the substance-
exposed MOC cultures. This might be an indicator of a slightly
less efficient nutrient supply through the Transwell1 mem-
brane. Nevertheless, the tissues accommodate a perfectly
stable long-term performance and, therefore, are very well-
suited for relevant substance testing protocols in the near
future. Finally, immunohistochemistry of the tissues revealed
further insights into their biology: Apoptosis was low in both
liver and skin tissues, suggesting an adequate supply of
nutrients throughout the whole culture period (Fig. 5a and b).
Fig. 5 Performance of Transwell1 multi-tissue cultures over 28 days. Evaluation of cell viability by a) TUNEL KI67 staining of liver tissue and b) TUNEL staining of skin
tissue after 28-day co-culture in MOC. Cell functionality was shown by immunostaining of c) Phase I enzymes cytochrome P450 3A4 (red) and cytochrome P450 7A1
(green) in liver tissue and d) Cytokeratin 15 (red) and cytokeratin 10 (green) showing both basal and stratified keratinocytes. e) Metabolic activity of the co-culture
analysed in culture supernatants. Data are means ¡ SEM (n = 4). Scale bars: a, b and d = 100 mm; c = 300 mm.
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Liver equivalents were stained for the expression of cyto-
chrome P450 3A4 and cytochrome P450 7A1 and skin biopsies
for Cytokeratin 10 and 15 to individually analyse the functions,
and thus, the degree of success, of the in vivo imitation of each
organ. Cytochrome P450 3A4 is an enzyme related to the
biotransformation of many xenobiotics, whereas cytochrome
P450 7A1 is involved in bile acid synthesis. The expression of
both proteins indicates the preservation of a metabolically
active phenotype over a culture period of up to 28 days
(Fig. 5c). Cytokeratin 15 is expressed in the basal keratinocytes
and cytokeratin 10 is expressed in keratinising and non-
keratinising stratified epithelia. We could demonstrate that
the skin’s epidermis still exhibited both basal and stratified
keratinocytes after 28 days of culture in the MOC (Fig. 5d); an
important factor showing the intact barrier function of the
skin. Hence, the MOC system is well-qualified for possible
long-term skin penetration and toxicity studies of two-tissue
cultures. The cellular metabolism of all tissues was measured
for 28 days in the MOC (Fig. 5e). Glucose consumption of the
co-cultures varied between different donors, but showed the
same trend throughout the culture period. This represents the
variety of individual response, which can be crucial for
substance testing. Both cell activity and metabolism prove
that the MOC system is able to cultivate a combination of two
tissues for 28 days with only minor reductions of viability and
cell activity. Thus, we were able to demonstrate that our MOC
system can be used for culturing various human tissues
derived from biopsies, primary cells and cell lines.
Furthermore, we were able to culture them in organotypical
3D tissue culture in a fluidic-linked manner, maintaining their
viability and characteristic functions for 28 days. Substances
could be applied onto the skin, for example, in the form of
creams, and penetration can be measured. Furthermore, the
combination of skin and liver equivalents in the MOC allows
one to analyse the effect of the (cosmetic) substances on the
liver, its metabolites and their further effect on the skin.
Prepuce biopsies are especially suitable for eye cosmetics due
to the similarity of its structure to the eyelid, and similar
bacterial flora.13 In addition, other skin biopsies, for example,
from the scalp or the abdomen, and commercially available
skin equivalents could be implemented, depending on the
appendages and glands needed for application, and sub-
stances tested.
Skin biopsies in Transwell1 holders achieved better results
for skin maintenance than those placed directly in the flow,
due to the air–liquid interface of the skin which is only
enabled in Transwell1 culture and allows the epidermal
differentiation in a similar manner to in vivo. When the skin
biopsies were submerged in the flow, the epidermis was
soaked and the shear stress led to premature degradation of
the epidermis.
Being able to cultivate biopsies of skin has huge advantages
compared with skin equivalents. The biopsies combine all cell
types of the human skin, including fibroblasts and keratino-
cytes, which are usually the only cell types in skin equivalents,
and others, such as Langerhans cells, melanocytes, endothelial
cells, and the natural extracellular matrix. Due to its
originality, the skin can mimic the in vivo situation best once
its characteristics can be maintained in vitro. Being able to
prepare and maintain biopsies in a reproducible and robust
manner encourages the transfer of other organs into this
system. We have achieved this transfer for hair follicles (data
not shown).
Exact in-process monitoring of oxygen consumption of the
individual tissues will be the next improvement to the MOC
platform. This is necessary in order to characterise the energy
balance of different tissues in various designs over extended
culture periods. The first indicative in-process measurements
of oxygen via the use of fluorescence quenching and an optical
fibre-assisted read-out system (Presense GmbH, Regensburg,
Germany) is described elsewhere.19,20 The oxygen consump-
tion has been explored via the easy optical access to each and
every position within the MOC. Another future development
target, which is currently in progress, is to improve test
throughput through process automation.
Conclusion
Co-cultures of human artificial liver microtissues and skin
biopsies, each a 1/100 000 of the biomass of their original
human organ counterparts, have successfully proven the long-
term performance of the novel microfluidic multi-organ-chip
device. The MOC design presented in this work assisted the co-
culture of the two tissues in two culture modes, directly
exposed to the fluid flow (proven by 14-day cultures) and
shielded from the underlying fluid flow by standard
Transwell1 inserts (proven by 28-day cultures). The latter
mode, in addition, facilitates the exposure of skin to the air-
liquid interface. The co-cultures, operated at a total on-chip
volume of 600 ml medium at recirculation rates of 40 ml min21
assisted by an on-chip micropump, stabilised at a metabolic
steady state within approximately a week. Furthermore, the
total fluid-to-tissue ratio in the system supports tissue cross-
talk, indicated by the consumption of liver tissue-produced
albumin by the skin. Finally, the co-cultures revealed a dose-
dependent response to a 6-day treatment with troglitazone at
the RNA level. This response was also pronounced when
looking at the LDH concentration in the medium and was not
detectable at the metabolic activity investigated here.
To summarise, our findings suggest that the MOC platform
is capable of comprehensively maintaining various tissues of
human origin (cell lines, primary cells and biopsies) over long
culture periods. MOC co-cultures can be exposed to pharma-
ceutical substances at regimens relevant to respective guide-
lines, currently used for subsystemic substance testing in
animals. Furthermore, the platform fits standardised micro-
tissue sizes (liver spheroids) and culture formats (Transwell1)
fully implemented in modern industrial substance screening
and increasingly accepted by regulatory bodies.
In-depth analysis of the yet undefined fluid flow character-
istics of the tissue culture compartments at current device
geometries are ongoing to ground a fundamental under-
standing of the robust long-term stability of the liver and skin
tissue co-cultures reported here.
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